David M. Loeb

David M. Loeb

Bunting-Blaustein Cancer Research Building, Room 2M51, 1650 Orleans Street, Baltimore, Maryland 21231
Tanzania

Publications
  • Research Article
    Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP
    Author(s): Breelyn A. Wilky and David M. LoebBreelyn A. Wilky and David M. Loeb

    Primary and metastatic malignant bone lesions result in significant pain and disability in oncology patients. Targeted bone-seeking radioisotopes including 153 Samarium ethylene-diamine-tetramethylene-phosphonic acid ( 153 Sm-EDTMP) have been shown to effectively palliate bone pain, often when external beam radiotherapy (EBRT) is not feasible. However, recent evidence also suggests 153 Sm-EDTMP has cytotoxic activity either alone or in combination with chemotherapy or EBRT. 153 Sm-EDTMP may be useful as anti-neoplastic therapy apart from pain palliation in a variety of malignancies. For prostate cancer patients, several phase I and II clinical trials have shown that combined 153 Sm-EDTMP and docetaxel-based chemotherapy can result in >50% decrease in prostate- specific antigen with manageable myelosuppression. In hematologic malignancies, 153 Sm-EDTMP produced cli.. View More»
    DOI: 10.4172/2161-1459.1000131

    Abstract PDF